'Kidney on a chip' device enables safer drug dosing: Study

Image
IANS New York
Last Updated : May 05 2016 | 1:22 PM IST

Using a "kidney on a chip" device that mimics the flow of medication through human kidneys and measure its effect on the ongan's cells can lead to safer drug dosing which is particularly critical for patients in intensive care units (ICUs), says a study.

"When you administer a drug, its concentration goes up quickly and it's gradually filtered out as it flows through the kidneys," said one of the researchers Shuichi Takayama, professor at University of Michigan in the US.

"A kidney on a chip enables us to simulate that filtering process, providing a much more accurate way to study how medications behave in the body," Takayamanoted.

Precise dosing in intensive care units is critical, as up to two-thirds of patients in the ICU experience serious kidney injury.

Medications contribute to this injury in more than 20 percent of cases, largely because many intensive care drugs are potentially dangerous to the kidneys.

Determining a safe dosage, however, can be surprisingly difficult. Today, doctors and drug developers rely mainly on animal testing to measure the toxicity of drugs and determine safe doses.

But animals process medications more quickly than humans, making it difficult to interpret test results and sometimes leading researchers to underestimate toxicity.

The new technique offers a more accurate way to test medications, closely replicating the environment inside a human kidney.

It uses a microfluidic chip device to deliver a precise flow of medication across cultured kidney cells.

"Even the same dose of the same drug can have very different effects on the kidneys and other organs, depending on how it's administered," Sejoong Kim, associate professor at Seoul National University Bundang Hospital in South Korea.

"This device provides a uniform, inexpensive way to capture data that more accurately reflects actual human patients," Kim noted.

In the study, the team tested their approach by comparing two different dosing regimens for gentamicin, an antibiotic that is commonly used in intensive care units.

They found that a once-daily dose of the medication is significantly less harmful than a continuous infusion--even though both cases ultimately delivered the same dose of medication.

The findings appeared in the journal Biofabrication.

--IANS

gb/vm

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: May 05 2016 | 1:10 PM IST

Next Story